TVTX

Travere Therapeutics, Inc.

9.80 USD
0.00 (0.00%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Travere Therapeutics, Inc. stock is up 41.01% since 30 days ago. The next earnings date is Aug 1, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 20 July’s closed higher than June. In the last 10 Unusual Options Trades, there were 7 PUTs, 3 CALLs.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
25 Jun 14:50 20 Dec, 2024 17.50 PUT 50 0
25 Jun 14:57 20 Dec, 2024 17.50 PUT 50 0
28 Jun 19:26 20 Sep, 2024 5.00 CALL 160 602
28 Jun 19:55 20 Dec, 2024 17.50 PUT 39 130
28 Jun 19:55 20 Dec, 2024 17.50 PUT 65 130
01 Jul 13:35 20 Dec, 2024 17.50 PUT 104 90
09 Jul 16:13 20 Dec, 2024 5.00 CALL 50 380
10 Jul 17:30 19 Dec, 2025 17.50 PUT 30 0
11 Jul 19:52 20 Dec, 2024 5.00 CALL 50 290
12 Jul 14:36 20 Dec, 2024 17.50 PUT 40 174

About Travere Therapeutics, Inc.

Travere Therapeutics, Inc. focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the. treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy.